Related Experiment Video
Updated: Feb 8, 2026
04:13
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
884
Mandibular Bisphosphonate Osteonecrosis: A Cautionary Tale.
The New York State Dental Journal
|June 20, 2018
Summary
Bisphosphonate (BP) therapy for bone disease requires timely dental care and prophylactic measures before dental surgery to prevent post-extraction complications like infection and bone death.
Area of Science:
- Oncology
- Dentistry
- Pharmacology
Background:
- Bisphosphonates (BPs) are potent drugs used to treat metastatic bone disease.
- Intravenous bisphosphonate infusions are common for managing skeletal-related events.
Observation:
- A 55-year-old female patient developed infection, suppuration, and sequestrum formation after mandibular extraction.
- The patient had previously received eight intravenous infusions of a potent bisphosphonate.
Findings:
- Delayed dental care following bisphosphonate administration can lead to severe complications.
- Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a significant risk.
Implications:
- Oncologists and dental practitioners must coordinate care for patients receiving bisphosphonates.
- Prophylactic dental evaluation and intervention are crucial before invasive dental procedures in BP patients.
